Barış Yaylak
Research Subjects
Barış Yaylak has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Utkan Sevuk
Department of Cardiovascular Surgery, Diyarbakir Education and Research Hospital, Diyarbakir, Turkey
8 shared publications - Fuat Polat
Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Educatıon Research Hospıtal, İstanbul, Turkey
6 shared publications - Sukru Akyuz
Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
6 shared publications - Tolga Onuk
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Education Research Hospital, Istanbul - Turquia
6 shared publications Erkan Baysal
5 shared publications- Ali Nazmi Çalık
UHS, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Cardiology Department, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 27 September 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5) , e20230791
Valor Prognóstico da Escore PRECİSE DAPT em Resultados de Curto e Longo Prazo em Pacientes MINOCA com Síndrome Coronariana Aguda
Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas [...] Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas
- 27 September 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5) , e20230791
Open AccessValor Prognóstico da Escore PRECİSE DAPT em Resultados de Curto e Longo Prazo em Pacientes MINOCA com Síndrome Coronariana Aguda
Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas [...] Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas
- Open Access
- 7 May 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5)
Prognostic Value of PRECİSE DAPT Score on Short- and Long-Term Outcomes in MINOCA Patients with Acute Coronary Syndrome
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) constitutes a significant subset of acute myocardial infarctions (AMI) with uncertain prognostic markers. Early risk assessment is crucial to identify MINOCA patients at risk of adverse outcomes. Objectives: This study aimed to evaluate the predictive capacity of the PRECISE-DAPT score in assessing short- and long-term prognoses in MINOCA patients presenting with ST-segment elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). Methods: Among 741 MINOCA patients, the PRECISE-DAPT score was computed to analyze its association with inhospital and follow-up major adverse cardiovascular events (MACE). Parameters showing significance in MACE (+) groups underwent statistical analysis: univariate logistic regression for in-hospital events and univariate Cox regression for follow-up events. For statistical significance, a predefined level of α = 0.05 was adopted. Parameters demonstrating significance proceeded to multiple logistic regression for in-hospital events and multivariate Cox regression for followup events. Results: In-hospital MACE occurred in 4.1% of patients, while 58% experienced follow-up MACE. Hemoglobin levels and the PRECISE-DAPT Score were identified as independent parameters for in-hospital MACE. Furthermore, ejection fraction (EF%) and the PRECISE-DAPT Score emerged as independent predictors of follow-up MACE. Conclusions: The study revealed that a higher PRECISE-DAPT score was significantly associated with increased risks of both in-hospital and long-term major adverse cardiovascular events in MINOCA patients presenting with acute coronary syndrome (ACS), underscoring the score’s potential in risk stratification for this patient cohort.
- 7 May 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5)
Open AccessPrognostic Value of PRECİSE DAPT Score on Short- and Long-Term Outcomes in MINOCA Patients with Acute Coronary Syndrome
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) constitutes a significant subset of acute myocardial infarctions (AMI) with uncertain prognostic markers. Early risk assessment is crucial to identify MINOCA patients at risk of adverse outcomes. Objectives: This study aimed to evaluate the predictive capacity of the PRECISE-DAPT score in assessing short- and long-term prognoses in MINOCA patients presenting with ST-segment elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). Methods: Among 741 MINOCA patients, the PRECISE-DAPT score was computed to analyze its association with inhospital and follow-up major adverse cardiovascular events (MACE). Parameters showing significance in MACE (+) groups underwent statistical analysis: univariate logistic regression for in-hospital events and univariate Cox regression for follow-up events. For statistical significance, a predefined level of α = 0.05 was adopted. Parameters demonstrating significance proceeded to multiple logistic regression for in-hospital events and multivariate Cox regression for followup events. Results: In-hospital MACE occurred in 4.1% of patients, while 58% experienced follow-up MACE. Hemoglobin levels and the PRECISE-DAPT Score were identified as independent parameters for in-hospital MACE. Furthermore, ejection fraction (EF%) and the PRECISE-DAPT Score emerged as independent predictors of follow-up MACE. Conclusions: The study revealed that a higher PRECISE-DAPT score was significantly associated with increased risks of both in-hospital and long-term major adverse cardiovascular events in MINOCA patients presenting with acute coronary syndrome (ACS), underscoring the score’s potential in risk stratification for this patient cohort.
- 20 February 2024
- Published by Wiley in Echocardiography
- Vol. 41 (2) , e15770
Comparison of echocardiographic and clinical characteristics in embolic stroke and migraine patients with patent foramen ovale
Background: This single‐center observational study aimed to compare the echocardiographic and clinical features in patients diagnosed with migraine and embolic stroke of undetermined source (ESUS) who presented with a known patent foramen ovale (PFO).Methods: Two‐dimensional and color Doppler images were obtained using various transthoracic echocardiography views for both migraine and ESUS patients. Suspected PFO cases underwent further assessment through contrast echocardiography and transesophageal echocardiography (TEE). High‐risk PFO characteristics were evaluated using TEE, and the Risk of Paradoxical Embolism (RoPe) score was calculated.Results: The study included 310 participants (age range: 18–60, 73.2% female), with 43.5% diagnosed with migraine and 56.5% with ESUS. Common comorbidities included diabetes (26.1%). High‐velocity shunting through the interatrial septum was observed in 35.5% of patients. ESUS patients were older, with higher rates of diabetes and hypertension, while active smoking was more prevalent among migraine patients. Basic echocardiographic parameters were mostly similar, except for elevated pulmonary artery systolic pressure in ESUS. ESUS patients exhibited a greater occurrence of large microbubble passage through the interatrial septum and longer PFO lengths compared to migraine patients. However, the RoPe and High‐risk PFO scores were similar between the groups.Conclusions: ESUS patients, characterized by older age and higher rates of diabetes and hypertension, demonstrated increased pulmonary artery pressure, more significant microbubble crossings, and longer PFO lengths. Conversely, migraine patients had a higher prevalence of active smoking. Despite differing clinical profiles, the risk scores for PFO‐related embolic events were comparable between the groups. These findings underscore potential distinctions between ESUS and migraine patients with PFO and their implications for management strategies.
- 20 February 2024
- Published by Wiley in Echocardiography
- Vol. 41 (2) , e15770
Comparison of echocardiographic and clinical characteristics in embolic stroke and migraine patients with patent foramen ovale
Background: This single‐center observational study aimed to compare the echocardiographic and clinical features in patients diagnosed with migraine and embolic stroke of undetermined source (ESUS) who presented with a known patent foramen ovale (PFO).Methods: Two‐dimensional and color Doppler images were obtained using various transthoracic echocardiography views for both migraine and ESUS patients. Suspected PFO cases underwent further assessment through contrast echocardiography and transesophageal echocardiography (TEE). High‐risk PFO characteristics were evaluated using TEE, and the Risk of Paradoxical Embolism (RoPe) score was calculated.Results: The study included 310 participants (age range: 18–60, 73.2% female), with 43.5% diagnosed with migraine and 56.5% with ESUS. Common comorbidities included diabetes (26.1%). High‐velocity shunting through the interatrial septum was observed in 35.5% of patients. ESUS patients were older, with higher rates of diabetes and hypertension, while active smoking was more prevalent among migraine patients. Basic echocardiographic parameters were mostly similar, except for elevated pulmonary artery systolic pressure in ESUS. ESUS patients exhibited a greater occurrence of large microbubble passage through the interatrial septum and longer PFO lengths compared to migraine patients. However, the RoPe and High‐risk PFO scores were similar between the groups.Conclusions: ESUS patients, characterized by older age and higher rates of diabetes and hypertension, demonstrated increased pulmonary artery pressure, more significant microbubble crossings, and longer PFO lengths. Conversely, migraine patients had a higher prevalence of active smoking. Despite differing clinical profiles, the risk scores for PFO‐related embolic events were comparable between the groups. These findings underscore potential distinctions between ESUS and migraine patients with PFO and their implications for management strategies.
- 16 February 2024
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 80 (5) , 759-770
Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year
ObjectiveThis retrospective study aimed to investigate the potential impact of ticagrelor and clopidogrel treatment on cardiovascular outcomes in patients with anemia and acute coronary syndrome (ACS) and to provide insights into the optimal therapeutic approach for this vulnerable patient population.MethodsA retrospective research design was employed, involving patients diagnosed with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) between 2014 and 2021. Inclusion criteria required a hemoglobin level below 12 mg/dL and a minimum 12-month P2Y12 inhibitor treatment. Comprehensive clinical, biochemical, and echocardiographic data were collected from the hospital's electronic repository. The primary efficacy endpoint was major adverse cardiovascular events (MACE), encompassing total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke. Major hemorrhage was the primary safety endpoint. Secondary outcomes included total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke, individually.ResultsPatients treated with ticagrelor (n = 118) and clopidogrel (n = 538) were compared. No significant difference was observed in major adverse cardiovascular events (MACE) and major bleeding between ticagrelor and clopidogrel treatment groups (MACE: clopidogrel 10.0% vs. ticagrelor 11.0%, p = 0.75; major bleeding: clopidogrel 2.8%, ticagrelor 2.5%, p = 0.88). Patients with hemoglobin levels <= 8 mg/dL demonstrated significantly higher MACE and major bleeding rates in the ticagrelor group (p = 0.008 and p = 0.002, respectively). Among patients aged >= 75 years, ticagrelor treatment was associated with a higher risk of major bleeding (p = 0.04).ConclusionsTicagrelor and clopidogrel exhibited comparable efficacy and safety outcomes in anemic ACS patients over a one-year period. Although ticagrelor demonstrated superiority in reducing ischemic events, it is crucial to recognize the limitations of retrospective studies in informing clinical practice. This study offers valuable insights into tailoring antiplatelet therapy for anemic ACS patients and provides guidance for personalized treatment strategies, acknowledging the hypothesis-generating nature of retrospective analyses.
- 16 February 2024
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 80 (5) , 759-770
Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year
ObjectiveThis retrospective study aimed to investigate the potential impact of ticagrelor and clopidogrel treatment on cardiovascular outcomes in patients with anemia and acute coronary syndrome (ACS) and to provide insights into the optimal therapeutic approach for this vulnerable patient population.MethodsA retrospective research design was employed, involving patients diagnosed with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) between 2014 and 2021. Inclusion criteria required a hemoglobin level below 12 mg/dL and a minimum 12-month P2Y12 inhibitor treatment. Comprehensive clinical, biochemical, and echocardiographic data were collected from the hospital's electronic repository. The primary efficacy endpoint was major adverse cardiovascular events (MACE), encompassing total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke. Major hemorrhage was the primary safety endpoint. Secondary outcomes included total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke, individually.ResultsPatients treated with ticagrelor (n = 118) and clopidogrel (n = 538) were compared. No significant difference was observed in major adverse cardiovascular events (MACE) and major bleeding between ticagrelor and clopidogrel treatment groups (MACE: clopidogrel 10.0% vs. ticagrelor 11.0%, p = 0.75; major bleeding: clopidogrel 2.8%, ticagrelor 2.5%, p = 0.88). Patients with hemoglobin levels <= 8 mg/dL demonstrated significantly higher MACE and major bleeding rates in the ticagrelor group (p = 0.008 and p = 0.002, respectively). Among patients aged >= 75 years, ticagrelor treatment was associated with a higher risk of major bleeding (p = 0.04).ConclusionsTicagrelor and clopidogrel exhibited comparable efficacy and safety outcomes in anemic ACS patients over a one-year period. Although ticagrelor demonstrated superiority in reducing ischemic events, it is crucial to recognize the limitations of retrospective studies in informing clinical practice. This study offers valuable insights into tailoring antiplatelet therapy for anemic ACS patients and provides guidance for personalized treatment strategies, acknowledging the hypothesis-generating nature of retrospective analyses.
- 3 January 2024
- Published by Springer Nature in Herz
- Vol. 49 (4) , 302-308
The predictive value of PRECISE-DAPT score for long-term mortality in patients with acute coronary syndrome complicated by cardiogenic shock
Background Besides its primary clinical utility in predicting bleeding risk in patients with acute coronary syndrome (ACS), the PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Anti-Platelet Therapy) score may also be useful for predicting long-term mortality in ACS patients presenting with cardiogenic shock (CS) since several studies have reported an association between the score and certain cardiovascular conditions or events. The aim of the present study was to evaluate the utility of the PRECISE-DAPT score for predicting the long-term all-cause mortality in patients (n = 293) with ACS presenting with CS. Methods The PRECISE-DAPT score was calculated for each patient who survived in hospital, and the association with long-term mortality was studied. Median follow-up time was 2.7 years. The performance of the final model was determined with measurements of its discriminative power (Harrell’s and Uno’s C indices and time-dependent area under the receiver operating characteristic curve [AUC]) and predictive accuracy (coefficient of determination [R2] and likelihood ratio χ2). Hazard ratios (HRs) were used to assess the relationship between the variables of the model and long-term all-cause death. Results All-cause death occurred in 197 patients (67%). There was a positive association between the PRECISE-DAPT score (change from 17 to 38 was associated with an HR of 2.42 [95% CI: 1.59–3.68], R2 = 0.209, time-dependent AUC = 0.69) and the risk of death such that in the adjusted survival curve, the risk of mortality increased as the PRECISE-DAPT score increased. Conclusion The PRECISE-DAPT score may be a useful easy-to-use tool for predicting long-term mortality in patients with ACS complicated by CS.
- 3 January 2024
- Published by Springer Nature in Herz
- Vol. 49 (4) , 302-308
The predictive value of PRECISE-DAPT score for long-term mortality in patients with acute coronary syndrome complicated by cardiogenic shock
Background Besides its primary clinical utility in predicting bleeding risk in patients with acute coronary syndrome (ACS), the PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Anti-Platelet Therapy) score may also be useful for predicting long-term mortality in ACS patients presenting with cardiogenic shock (CS) since several studies have reported an association between the score and certain cardiovascular conditions or events. The aim of the present study was to evaluate the utility of the PRECISE-DAPT score for predicting the long-term all-cause mortality in patients (n = 293) with ACS presenting with CS. Methods The PRECISE-DAPT score was calculated for each patient who survived in hospital, and the association with long-term mortality was studied. Median follow-up time was 2.7 years. The performance of the final model was determined with measurements of its discriminative power (Harrell’s and Uno’s C indices and time-dependent area under the receiver operating characteristic curve [AUC]) and predictive accuracy (coefficient of determination [R2] and likelihood ratio χ2). Hazard ratios (HRs) were used to assess the relationship between the variables of the model and long-term all-cause death. Results All-cause death occurred in 197 patients (67%). There was a positive association between the PRECISE-DAPT score (change from 17 to 38 was associated with an HR of 2.42 [95% CI: 1.59–3.68], R2 = 0.209, time-dependent AUC = 0.69) and the risk of death such that in the adjusted survival curve, the risk of mortality increased as the PRECISE-DAPT score increased. Conclusion The PRECISE-DAPT score may be a useful easy-to-use tool for predicting long-term mortality in patients with ACS complicated by CS.
- Open Access
- 31 October 2023
- Published by Wiley
The role of pacemaker in the prevention of atrial fibrillation in patients with sick sinus syndrome
Objective: This retrospective study examined the relationship between atrial pacing parameters and atrial fibrillation (AF) occurrence in patients with sick sinus syndrome (SSS) who received dual-chamber pacemakers. Methods: Sixty SSS patients who underwent dual pacemaker implantation were studied. Demographics, clinical data, and device information were collected, and patients were followed for up to 2 years post-implantation. Statistical analyses assessed the association between atrial pacing parameters and AF development. Receiver operating characteristic (ROC) analysis identified potential predictors of AF, focusing on atrial pacing frequency and mode switch episodes. Results: Higher atrial pacing frequency significantly reduced AF risk at all time points (pConclusion: Maintaining a higher atrial pacing frequency emerges as a valuable strategy to reduce AF risk in dual-chamber pacemaker recipients with SSS. Notably, atrial premature beats and mode-switching episodes primarily influenced AF risk during the early post-implantation phase. This underscores the importance of monitoring and optimizing atrial pacing parameters, especially in the initial stages following pacemaker implantation, for effective AF management in SSS patients.
- 31 October 2023
- Published by Wiley
Open AccessThe role of pacemaker in the prevention of atrial fibrillation in patients with sick sinus syndrome
Objective: This retrospective study examined the relationship between atrial pacing parameters and atrial fibrillation (AF) occurrence in patients with sick sinus syndrome (SSS) who received dual-chamber pacemakers. Methods: Sixty SSS patients who underwent dual pacemaker implantation were studied. Demographics, clinical data, and device information were collected, and patients were followed for up to 2 years post-implantation. Statistical analyses assessed the association between atrial pacing parameters and AF development. Receiver operating characteristic (ROC) analysis identified potential predictors of AF, focusing on atrial pacing frequency and mode switch episodes. Results: Higher atrial pacing frequency significantly reduced AF risk at all time points (pConclusion: Maintaining a higher atrial pacing frequency emerges as a valuable strategy to reduce AF risk in dual-chamber pacemaker recipients with SSS. Notably, atrial premature beats and mode-switching episodes primarily influenced AF risk during the early post-implantation phase. This underscores the importance of monitoring and optimizing atrial pacing parameters, especially in the initial stages following pacemaker implantation, for effective AF management in SSS patients.
- 19 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1186-1197
The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long‐term cardiovascular events
Introduction: Drug‐eluting stents (DES) have revolutionized percutaneous coronary intervention (PCI) by improving event‐free survival compared to older stent designs. However, early‐generation DES with polymer matrixes have raised concerns regarding late stent thrombosis due to delayed vascular healing. To address these issues, biologically bioabsorbable polymer drug‐eluting stents (BP‐DES) and polymer‐free drug‐eluting stents (PF‐DES) have been developed.Aim: The aim of the present study is to evaluate and compare the long‐term effects of different stent platforms in patients with acute coronary syndrome (ACS) undergoing PCI.Material and Methods: We conducted a retrospective, observational study involving 1192 ACS patients who underwent urgent PCI. Patients were treated with thin‐ strut DP‐DES, ultra‐thin strut BP‐DES, or thin‐strut PF‐DES. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (CITLR) at 12 months and 4 years.Results: The baseline demographics and clinical characteristics of patients in the three stent subgroups were similar. No significant differences were observed in target lesion failure (TLF), cardiac mortality, TVMI, and stent thrombosis (ST) rates among the three subgroups at both 12 months and 4 years. However, beyond the first year, the rate of CITLR was significantly lower in the ultra‐thin strut BP‐DES subgroup compared to thin‐strut DP‐DES, suggesting potential long‐term advantages of ultra‐thin strut BP‐DES. Additionally, both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrated lower ST rates after the first year compared to thin‐strut DP‐DES.Conclusion: Our study highlights the potential advantages of ultra‐thin strut BP‐DES in reducing CITLR rates in the long term, and both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrate lower rates of ST beyond the first year compared to thin‐strut DP‐DES. However, no significant differences were observed in overall TLF, cardiac mortality and TVMI rates among the three stent subgroups at both 12 months and 4 years.
- 19 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1186-1197
The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long‐term cardiovascular events
Introduction: Drug‐eluting stents (DES) have revolutionized percutaneous coronary intervention (PCI) by improving event‐free survival compared to older stent designs. However, early‐generation DES with polymer matrixes have raised concerns regarding late stent thrombosis due to delayed vascular healing. To address these issues, biologically bioabsorbable polymer drug‐eluting stents (BP‐DES) and polymer‐free drug‐eluting stents (PF‐DES) have been developed.Aim: The aim of the present study is to evaluate and compare the long‐term effects of different stent platforms in patients with acute coronary syndrome (ACS) undergoing PCI.Material and Methods: We conducted a retrospective, observational study involving 1192 ACS patients who underwent urgent PCI. Patients were treated with thin‐ strut DP‐DES, ultra‐thin strut BP‐DES, or thin‐strut PF‐DES. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (CITLR) at 12 months and 4 years.Results: The baseline demographics and clinical characteristics of patients in the three stent subgroups were similar. No significant differences were observed in target lesion failure (TLF), cardiac mortality, TVMI, and stent thrombosis (ST) rates among the three subgroups at both 12 months and 4 years. However, beyond the first year, the rate of CITLR was significantly lower in the ultra‐thin strut BP‐DES subgroup compared to thin‐strut DP‐DES, suggesting potential long‐term advantages of ultra‐thin strut BP‐DES. Additionally, both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrated lower ST rates after the first year compared to thin‐strut DP‐DES.Conclusion: Our study highlights the potential advantages of ultra‐thin strut BP‐DES in reducing CITLR rates in the long term, and both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrate lower rates of ST beyond the first year compared to thin‐strut DP‐DES. However, no significant differences were observed in overall TLF, cardiac mortality and TVMI rates among the three stent subgroups at both 12 months and 4 years.
- 1 April 2018
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (8) , e77
The Relationship between Coronary Collateral Circulation and in-Hospital Mortality in Patients with First Acute Anterior Stemı
- 1 April 2018
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (8) , e77
The Relationship between Coronary Collateral Circulation and in-Hospital Mortality in Patients with First Acute Anterior Stemı
- Open Access
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 14 (4) , 383-390
Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention
Introduction The primary goal in the management of acute ST segment elevation myocardial infarction (STEMI) is to open the occluded artery at an early stage. The development of no-reflow is multifactorial, and the etiology is not fully understood. There is accumulating evidence that anemia is...
- 1 January 2018
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 14 (4) , 383-390
Open AccessRelation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention
Introduction The primary goal in the management of acute ST segment elevation myocardial infarction (STEMI) is to open the occluded artery at an early stage. The development of no-reflow is multifactorial, and the etiology is not fully understood. There is accumulating evidence that anemia is...
- 20 December 2017
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 20 (3) , 256-258
Iloprost is a Useful Therapy for Adams-Oliver Syndrome with Eisenmenger Syndrome
- 20 December 2017
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 20 (3) , 256-258
Iloprost is a Useful Therapy for Adams-Oliver Syndrome with Eisenmenger Syndrome